VANCOUVER, British Columbia, Oct. 19, 2016 /PRNewswire/ -- 23andMe, Inc. today announced a grant program as part of its
Proposals will be selected based on scientific significance, approach, feasibility, investigator expertise, innovativeness of the project and inclusion of the evaluation of the impact of return of genetic information on participant engagement. Educational institutions, universities and research centers performing genomics research in the United States are eligible.
Two proposals will be selected from among the program submissions; each will receive 200 23andMe DNA Collection kits for their prospective genotyping study. Beginning today, interested researchers can apply to the grant program at the following http://researchers.23andme.org/grant-program.
"At 23andMe our model is to treat research participants as true partners," said Ruby Gadelrab, 23andMe vice president of commercial marketing. "We find that study participants are much more engaged when they have the opportunity to learn about their personal genetic information, and this makes recruitment for research studies much easier."
The announcement of the grant program is part of a major company presence at the American Society of Human Genetics (ASHG) Annual Meeting, the world's largest gathering of human genetics researchers, this week in Vancouver. The company is presenting insights on the landmark population health study its powering in collaboration with Nevada-based health system Renown Health and the Desert Research Institute (DRI), which recruited more than 10,000 study volunteers in less than 48 hours. The study's principal investigator, Joe Grzymski, Ph.D., from DRI will be sharing information on the study and insights gleaned in the recruiting process.
The presentation will headline 23andMe's educational seminar, New Models in Genotyping: Incentivizing Recruitment, Engaging Participants and Accelerating Research Results. The seminar takes place Thursday, Oct. 20 from 1:00-2:30 p.m. in Ballroom B, East Building, Vancouver Convention Centre. Following is a full list of seminar topics:
In addition, Richard Scheller, Ph.D., 23andMe chief science officer and head of therapeutics, is speaking today, Wednesday, Oct. 19, on the topic From GWAS and Mendelian Genes to Therapeutic Drug Targets.
23andMe scientists also have a number of scheduled platform and poster presentations on topics ranging from nail biting to body mass index (BMI).
23andMe posters (on display throughout conference):
There are also a number of presentations and posters by 23andMe collaborators.
About 23andMe23andMe, Inc. is the leading personal genetics company. Founded in 2006, the mission of the company is to help people access, understand and benefit from the human genome. 23andMe has more than one million customers worldwide, with over 80 percent consented to participate in research. 23andMe, Inc. is located in Mountain View, CA. More information is available at www.23andMe.com.
Andy Kill(650) [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/23andme-launches-genotyping-services-for-research-grant-program-300347431.html
SOURCE 23andMe, Inc.
Subscribe to our Free Newsletters!
Schizoaffective disorder is a serious mental disorder in which the individual reflects symptoms ...
When a person overeats, he is unable to control his hunger pangs, while during an emotional/binge ...
Hypoplastic left heart syndrome is a rare congenital condition, which affects normal blood ...View All